Related Experiment Videos
Cancer therapy and polymorphisms of cytochromes P450
S L MacLeod1, S Nowell, J Massengill
1University of Arkansas for Medical Sciences and Arkansas Cancer Research Center, Little Rock, USA.
Abstract:
Cytochrome P450 (CYP) enzymes are important in the metabolism of some endogenous compounds, environmental and dietary xenobiotics and many drugs. Many of these enzymes have genetic polymorphisms that produce significant changes in metabolic activity, however the function of other polymorphisms is unknown. Genetic polymorphisms have important influences on variability in human pharmacokinetics, including intra-individual differences in drug toxicity, drug interactions and response to chemotherapy. Other factors that influence drug metabolism include differences in enzyme expression due to differences in age, gender, smoking status, exposure to dietary or environmental xenobiotics or co-administration of other drugs. In addition, some xenobiotics and drugs can directly inhibit or induce the activity of CYPs. All of these factors can produce differences in metabolic capacities among individuals which can produce toxicity in some patients and sub-effective dosing in others. Maximum clinical benefit will require a more complete understanding of the influence of these polymorphisms on allele function and their interaction with inducers and inhibitors of enzyme expression or activity. This effort will permit the pharmacogenetic screening of patients before the administration of drugs and result in the identification of individuals who are prone to adverse reactions or poor response, resulting in more effective individualized therapy.
Insights
Genetic variations in Cytochrome P450 (CYP) enzymes significantly impact drug metabolism and patient response. Understanding these genetic polymorphisms is key to preventing adverse drug reactions and optimizing individualized therapy.
Area of Science:
- Pharmacogenetics
- Drug Metabolism
- Enzyme Kinetics
Background:
- Cytochrome P450 (CYP) enzymes are crucial for metabolizing endogenous compounds, xenobiotics, and drugs.
- Genetic polymorphisms in CYP enzymes lead to significant variations in metabolic activity, affecting drug pharmacokinetics.
- Factors like age, gender, smoking, and drug interactions also influence CYP enzyme activity and drug response.
Purpose of the Study:
- To explore the impact of genetic polymorphisms on CYP enzyme function and drug metabolism.
- To understand how genetic variations influence drug toxicity, interactions, and therapeutic outcomes.
- To highlight the need for a comprehensive understanding of CYP polymorphisms for personalized medicine.
Main Methods:
- Review of existing literature on CYP enzyme genetics and drug metabolism.
- Analysis of factors influencing inter-individual variability in drug response.
- Discussion of the clinical implications of CYP genetic polymorphisms.
Main Results:
- Genetic polymorphisms in CYP enzymes are a major source of variability in human pharmacokinetics.
- These variations can lead to drug toxicity in some patients and sub-effective dosing in others.
- Understanding CYP polymorphisms is essential for predicting patient response to drugs.
Conclusions:
- A deeper understanding of CYP genetic polymorphisms and their interactions with inducers/inhibitors is necessary for clinical benefit.
- Pharmacogenetic screening can identify individuals at risk for adverse drug reactions or poor response.
- Individualized therapy based on genetic profiles promises more effective and safer patient treatment.